| Literature DB >> 30618851 |
Alessandra Fusco1, Vittoria Savio1, Anna De Filippis1, Antonio Tufano2, Giovanna Donnarumma1.
Abstract
Bacterial prostatitis is believed to be the leading cause of recurrent urinary tract infections (UTIs) in men under 50 years of age and occurs both as an acute febrile disease responsive to antibiotics and as a chronic infection that is often unresponsive to antibiotic treatment. Proteus mirabilis is more commonly associated with UTIs in these abnormalities, especially in patients undergoing catheterisation. This pathogen is able to colonise the host's tissues and to cause disease thanks to the production of many virulence factors such as fimbriae, flagella, immune avoidance, host-damaging factors, and the ability to form crystalline biofilms. In addition, Proteus lipid A may exhibit apoptotic activity and induce desquamation of epithelial cells. The aim of this work was to evaluate the ability of two clinically isolated strains of P. mirabilis that are phenotypically different, named PM1 of PM2, respectively, to induce apoptosis in human prostatic adenocarcinoma PC-3. Our results demonstrate that PM1 and PM2 are able to activate two different apoptotic pathways, and this different behaviour is confirmed by the expression level of the ZapA gene, molecular fingerprinting and different spectrum of antibiotic resistance. The identification and knowledge of relations between the microorganism and host may provide the basis for new solutions to clinical problems with regard to diagnosis and therapy.Entities:
Keywords: Proteus; UTIs; antibiotic resistance; apoptosis; prostatitis
Year: 2018 PMID: 30618851 PMCID: PMC6306403 DOI: 10.3389/fphys.2018.01855
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Primers sequence for RAPD-PCR.
| Gene | Sequence | Total number of bands | Total number of the band in Proteus | Number of the polymorphic band in Proteus | Simpson’s diversity index (DI) |
|---|---|---|---|---|---|
| OPA10 | 5′-GTGATCGCAG-3′ | 23 | 5 | 3 | 0.756 |
| OPA11 | 5′-CAATCGCCGT-3′ | 31 | 12 | 9 | 0.899 |
| OPD20 | 5′-ACCCGGTCAC-3′ | 9 | 3 | 2 | 0.333 |
| OPX13 | 5′-ACGGGAGCAA-3′ | 23 | 13 | 9 | 0.921 |
| OPX15 | 5′-CAGACAAGCC-3′ | 15 | 8 | 2 | 0.563 |
| OPZ04 | 5′-AGGCTGTGCT-3′ | 11 | 7 | 1 | 0.335 |
| OPZ08 | 5′-GGGTGGGTAA-3′ | 15 | 10 | 8 | 0.884 |
| OPZ10 | 5′-CCGACAAACC-3′ | 16 | 7 | 5 | 0.627 |
| OPZ19 | 5′-GTGCGAGCAA-3′ | 26 | 14 | 7 | 0.847 |
| OPZ20 | 5′-ACTTTGGCGG-3′ | 19 | 7 | 5 | 0.945 |
| 188 | 86 | 51 | 0.998 | ||
Primers sequence for real-time PCR.
| Primers sequence | Conditions | Product size (bp) | |
|---|---|---|---|
| BAX | 5′-TGGCAGCTGACATGTTTTCTGAC-3′ | 5″ at 94°C, 4″ at 56°C, 8″ at 72°C for 40 cycles | 200 |
| Bcl-2 | 5′-CAGCTGCACCTGACGCCCTT-3′ | 5″ at 94°C, 7″ at 58°C, 9″ at 72°C for 40 cycles | 235 |
| TNF-R1 | 5′-ACCAAGTGCCACAAAGGAAC-3′ | 5″ at 95°C, 5″ at 53°C, 10″ at 72°C for 40 cycles | 263 |
| Fas-L | 5′-GGATTGGGCCTGGGGATGTTTCA-3′ | 5″ at 95°C, 7″ at 60°C, 14″ at 72°C for 40 cycles | 344 |
| Fas-R | 5′-CCAAGTGACTGACATCAACTC-3′ | 5” at 94 °C, 8” at 55 °C, 17” at 72 °C for 40 cycles | 426 |
| p53 | 5′-TTCTTGCATTCTGGGACAGCC-3′ | 5” at 94 °C, 13” at 56 °C, 26” at 72 °C for 40 cycles | 650 |
| Caspase-3 | 5′-TTAATAAAGGTATCCATGGAGAACACT-3′ | 5” at 94 °C, 17” at 55 °C, 33” at 72 °C for 40 cycles | 838 |
| Caspase-6 | 5′-GGACCACAGGAGGAGAGGAATTGC-3′ | 5” at 94 °C, 6” at 59 °C, 13” at 72 °C for 40 cycles | 317 |
| Caspase-8 | 5′-CTGCTGGGGATGGCCACTGTG-3′ | 5” at 94 °C, 15” at 60 °C, 15” at 72 °C for 40 cycles | 380 |
| Caspase-9 | 5′-TTCCCAGGTTTTGTTTCCTG-3′ | 5” at 94 °C, 3” at 55 °C, 6” at 72 °C for 40 cycles | 143 |
| TNF-α | 5′-CAGAGGGAAGAGTTCCCCAG-3′ | 5″ at 95°C, 6″ at 57°C, 13″ at 72°C for 40 cycles | 324 |
FIGURE 1Molecular profiles obtained by RAPD-PCR for PM1 and PM2.
Antimicrobial susceptibility profiles of PM1 and PM2 isolates when interpreted using PhoenixTM (BD diagnostic systems).
| PM1 | PM2 | |||
|---|---|---|---|---|
| ANTIBIOTIC | MIC/Conc. | SIR | MIC/Conc. | SIR |
| Amikacin | 8 | S | <=4 | S |
| Amoxicillin-Clavulanic acid | <=2/2 | S | >32/2 | R |
| Ampicillin | <=2 | S | >8 | R |
| Cefepime | <=1 | S | <=1 | S |
| Cefotaxime | <=1 | S | <=1 | S |
| Ceftazidime | <=0.5 | S | <=0.5 | S |
| Cefuroxime | <02 | S | >8 | R |
| Ciprofloxacin | <=0.25 | S | <=0.25 | S |
| Colistin | >4 | R | >4 | R |
| Ertapenem | <=0.25 | S | <=0.25 | S |
| Fosfomycin c/G6P | <=16 | S | 64 | R |
| Gentamicin | 4 | I | 2 | S |
| Levofloxacin | <=0.5 | S | <=0.5 | S |
| Meropenem | <=0.5 | S | <=0.5 | S |
| Piperacillin | <=4 | S | <=4 | S |
| Piperacillin-tazobactam | <=4/4 | S | <=4.4 | S |
| Tigecycline | R | R | ||
| Tobramycin | 4 | I | 2 | S |
| Trimethoprim-sulfamethoxazole | <=1/19 | S | <=1/19 | S |
FIGURE 2ZapA gene expression in PM1 and PM2 growth in LB broth; data are expressed as percentages of mRNA levels in each sample normalised to 16S RNA. Data are mean ± SD.
FIGURE 3Skimmed milk agar test. Around the colonies of only PM1 large clear zone, due to the proteolysis of casein, are clearly visible.
FIGURE 4Comparison between relative gene expression (A) and protein concentration (B) of apoptotic factors in PC3 cells with PM1 and PM2. Data are mean ± SD and are expressed as percentages of mRNA levels in each group compared to unstimulated cells (CTRL).
MTT assay: spectrophotometric absorbance values at 570 nm.
| SAMPLE | O.D. |
|---|---|
| PC-3 | 2.9 |
| PC-3 + PM1 | 2.613 |
| PC-3 + PM2 | 0.733 |